Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Holding CARA?
Track your performance easily
CARA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.24 - $1.31
Previous Close$0.31
Volume59.37K
Average Volume (3M)518.97K
Market Cap
$16.51M
Enterprise Value-$22.11M
Total Cash (Recent Filing)$42.04M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding54,855,514
10 Day Avg. Volume999,256
30 Day Avg. Volume518,967
Standard Deviation0.21
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)30.50
Price to Sales (P/S)1.90
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.10
Enterprise Value/Gross Profit-1.49
Enterprise Value/Ebitda0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cara Therapeutics News
Ownership Overview
2.97% Insiders
5.02% Mutual Funds
8.55% Other Institutional Investors
79.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CARA FAQ
What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $0.24 and its highest was $1.31 in the past 12 months.
What is Cara Therapeutics’s market cap?
Currently, no data Available
When is Cara Therapeutics’s upcoming earnings report date?
Cara Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 97 days.
How were Cara Therapeutics’s earnings last quarter?
Cara Therapeutics released its earnings results on Nov 04, 2024. The company reported -$0.228 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.012.
Is Cara Therapeutics overvalued?
According to Wall Street analysts Cara Therapeutics’s price is currently Overvalued.
Does Cara Therapeutics pay dividends?
Cara Therapeutics does not currently pay dividends.
What is Cara Therapeutics’s EPS estimate?
Cara Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cara Therapeutics have?
Cara Therapeutics has 54,855,515 shares outstanding.
What happened to Cara Therapeutics’s price movement after its last earnings report?
Cara Therapeutics reported an EPS of -$0.228 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Cara Therapeutics?
Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 479K.
---
Cara Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.22%
12-Months-Change
Fundamentals
Return on Equity
-221.25%
Trailing 12-Months
Asset Growth
-55.50%
Trailing 12-Months
Company Description
Cara Therapeutics
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
---
CARA Earnings Call
Q4 2024
0:00 / 0:00
---
CARA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Corcept Therapeutics
―
Kiniksa Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Aurinia Pharmaceuticals
―
---